Peste des Petits Ruminants (PPR) in India Epidemiology and ControlBhoj Raj Singh
PPR is endemic in India in sheep & goats. Mainly young stocks are more affected. Disease occurs throughout the year but more common in October & March. Though vaccination is the only method for control & eradication, even the institutes those developed the effective vaccine in India to control the disease fear to use it because many a time outbreaks ensue on vaccination. The other important reason for persistence of disease is undeclared Policy of suppressed reporting of PPR outbreaks.
Lumpy skin disease (LSD) Globally and in India.pptxBhoj Raj Singh
LSD has emerged as a dairy industry devastating disease in India in the last four years. First noticed in Orrisa and is now present all over India. Recurring outbreaks are now noticed in Rajasthan, Uttarakhand and other states indicating that the disease is becoming endemic in India.
There are hundreds of diseases of livestock and pet animals that can be printed through properly used quality vaccines. This presentation summarises different types of vaccines used by veterinarians to control/ prevent diseases. The presentation enlists the vaccine-preventable diseases of pets and livestock, and also the different vaccines used.
Common cattle diseases by Dr.Pavulraj.S, M.V.Sc., Pathology scholar, IVRI (NR...Pavulraj Selvaraj
important bacterial, viral and parasitic diseases of cattle with good quality images for veterinarians in filed and college as well for better diagnosis of diseases in quick review form in presentation mode
local names, definition, etiology,epidemiology lifecycle, pathogenesis, clinical findings, necropsy finding, diagnosis,treatment, control and prevention
Control and Eradication of Animal diseases.pptxBhoj Raj Singh
The presentation details different methods and terminologies used in disease management. It briefs about different types of disease control programs run at global, regional, and national levels. It also tells about the success and failure of different disease control programs. The presentation also briefed about methods of disease control.
Peste des Petits Ruminants (PPR) in India Epidemiology and ControlBhoj Raj Singh
PPR is endemic in India in sheep & goats. Mainly young stocks are more affected. Disease occurs throughout the year but more common in October & March. Though vaccination is the only method for control & eradication, even the institutes those developed the effective vaccine in India to control the disease fear to use it because many a time outbreaks ensue on vaccination. The other important reason for persistence of disease is undeclared Policy of suppressed reporting of PPR outbreaks.
Lumpy skin disease (LSD) Globally and in India.pptxBhoj Raj Singh
LSD has emerged as a dairy industry devastating disease in India in the last four years. First noticed in Orrisa and is now present all over India. Recurring outbreaks are now noticed in Rajasthan, Uttarakhand and other states indicating that the disease is becoming endemic in India.
There are hundreds of diseases of livestock and pet animals that can be printed through properly used quality vaccines. This presentation summarises different types of vaccines used by veterinarians to control/ prevent diseases. The presentation enlists the vaccine-preventable diseases of pets and livestock, and also the different vaccines used.
Common cattle diseases by Dr.Pavulraj.S, M.V.Sc., Pathology scholar, IVRI (NR...Pavulraj Selvaraj
important bacterial, viral and parasitic diseases of cattle with good quality images for veterinarians in filed and college as well for better diagnosis of diseases in quick review form in presentation mode
local names, definition, etiology,epidemiology lifecycle, pathogenesis, clinical findings, necropsy finding, diagnosis,treatment, control and prevention
Control and Eradication of Animal diseases.pptxBhoj Raj Singh
The presentation details different methods and terminologies used in disease management. It briefs about different types of disease control programs run at global, regional, and national levels. It also tells about the success and failure of different disease control programs. The presentation also briefed about methods of disease control.
etiology, local names, definition, transmission, source of infection, epidemiology, pathogenesis, clinical signs, diagnosis, differential diagnosis, treatment prevention and control
Presentation by Delia Grace at the first United Nations Environment Programme (UNEP) Science-Policy Forum ahead of the Second Session of the United Nations Environment Assembly (UNEA-2), Nairobi, Kenya, 20 May 2016.
Prepared for Delmarva Small Ruminant Conference: All Worms All Day -- by Dr. Niki Whitley. Delaware State University, Dover, Delaware, December 9, 2017.
etiology, local names, definition, transmission, source of infection, epidemiology, pathogenesis, clinical signs, diagnosis, differential diagnosis, treatment prevention and control
Presentation by Delia Grace at the first United Nations Environment Programme (UNEP) Science-Policy Forum ahead of the Second Session of the United Nations Environment Assembly (UNEA-2), Nairobi, Kenya, 20 May 2016.
Prepared for Delmarva Small Ruminant Conference: All Worms All Day -- by Dr. Niki Whitley. Delaware State University, Dover, Delaware, December 9, 2017.
Fowl adenovirus: Using serology to control your flocksRafael Monleon
A presentation about Fowl Adenovirus in chickens. It provides insights on: etiology, pathology, monitoring and control among others.
Presented globally on September 9th 2014 via Watt Ag-Net Webinar by Dr. Rafael Monleon
Contact me in LinkedIn for any question: www.linkedin.com/rafaelmonleon
This ppt provide information about the conventional methods of animal vaccine production..it is somewhat differ from my earlier ppt of vaccine production techniques..
Monitor and Control of Vertically Transmitted Poultry DiseasesRafael Monleon
A presentation covering the monitor and control of common vertically transmitted diseases in poultry with concentration in chickens.
Presented at various locations including BioChek Seminar in Manila, Philippines in 2014 by Dr. Rafael Monleon
Contact me in LinkedIn for any question: www.linkedin.com/rafaelmonleon
Focus on Enteric Health: The advent of a Poultry Industry without AGPsRafael Monleon
A presentation covering the topic of removal of AGPs from the poultry production.
Presented at the Korean Poultry Science Association in May 2011 by Dr. Rafael Monleon
Contact me in LinkedIn for any question: www.linkedin.com/rafaelmonleon
POLICY SEMINAR
Virtual Event - Building back better: How can public food and agricultural research institutions be strengthened and rebuilt after the COVID-19 pandemic?
Co-Organized by IFPRI and the International Consortium on Applied Bioeconomic Research (ICABR)
FEB 2, 2021 - 09:30 AM TO 11:00 AM EST
Potential impacts of COVID-19 research on livestock health research and innov...ILRI
Presentation by Vish Nene at a virtual event on Building back better: How can public food and agricultural research institutions be strengthened and rebuilt after the COVID-19 pandemic?, 2 February 2021.
Dr. Jim Roth - Foreign Animal Disease Prep: What Should You Know?John Blue
Foreign Animal Disease Prep: What Should You Know? - Dr. Jim Roth, Iowa State University, from the 2018 Iowa Pork Congress, January 24 - 25, 2018, Des Moines, IA, USA.
More presentations at http://www.swinecast.com/2018-iowa-pork-congress
Dr. James A. Roth - FMD Vaccination: Preparedness, Availability, and LimitationsJohn Blue
FMD Vaccination: Preparedness, Availability, and Limitations - James Roth, DVM, Director, Center for Food Security and Public Health and Executive Director, Institute for International Cooperation in Animal Biologics, Iowa State University, from the 2014 NIAA Annual Conference titled 'The Precautionary Principle: How Agriculture Will Thrive', March 31 - April 2, 2014, Omaha, NE, USA.
More presentations at http://www.trufflemedia.com/agmedia/conference/2014_niaa_how_animal_agriculture_will_thrive
Genetic selection for disease resistance (animal breeding). اصلاح دامMohammad Ghaderzadeh
Mohammad Ghaderzadeh
Ph.D candidate in Animal Breeding & Genetics, Sari Agricultural Sciences and Natural Resources University, Iran
انتخاب ژنتیکی برای مقاومت در دام و طیور
Relations between pathogens, hosts and environmentEFSA EU
Presentation of the EFSA's second scientific conference, held on 14-16 October 2015 in Milan, Italy.
DRIVERS FOR EMERGING ISSUES IN ANIMAL AND PLANT HEALTH
Dr. Robert Tauxe - Public Health Concerns About Resistant Foodborne InfectionsJohn Blue
Public Health Concerns About Resistant Foodborne Infections - Dr. Robert Tauxe, Deputy Director, Division of Foodborne, Waterborne and Environmental Infections, Centers for Disease Control and Prevention, from the 2013 NIAA Symposium Bridging the Gap Between Animal Health and Human Health, November 12-14, 2013, Kansas City, MO, USA.
More presentations at http://www.trufflemedia.com/agmedia/conference/2013-niaa-antibiotics-bridging-the-gap-animal-health-human-health
Foot and mouth disease preventive and epidemiological aspectsBhoj Raj Singh
FMD: Menace in India
Discusses problems of FMD Control in India like:
Lack of faith in farmers and veterinarians that FMD can be controlled with vaccination (due to repeated failure of vaccines in quality and vaccination failures resulting in FMD outbreaks).
Lack of infrastructure facilities for maintaining the cold chain and efficient transport to the vaccination site.
Lack of human resources for handling/ vaccinating livestock.
Needs for further researches on diagnosis (Pen-side), disinfection, vaccines and vaccination (affording at least a year immunity, quality vaccine etc.) and control strategies.
No-timely investigation or excessively delayed investigation of FMD outbreaks especially those occurring after vaccination.
Transparency in vaccine quality monitoring and vaccine purchases.
Fear in veterinarians for reporting FMD in their area of operation.
False statistics of the disease and vaccination.
No legal punitive action against suppliers of substandard FMD vaccines even after the supply of multiple substandard batches of vaccine.
Vaccines and diagnostics—The case for regional One Health centres of excellence ILRI
Presented Delia Grace, Phil Toye, Shirley Tarawali and Vish Nene at the Workshop on One Health Colloquium: Sustainable Livestock and Disease Control—Exploring the Links to Climate Change, Improving Human Nutrition and the Refugee Crisis, London, 31 May–1 June 2016
Presentation by Delia Grace, Bernard Bett, Christine Atherstone, Fred Unger, Hung Nguyen-Viet and Sinh Dang-Xuan at the Australian Veterinary Association Annual Conference, Perth, Australia, 5–10 May 2019.
Item 9: Soil mapping to support sustainable agricultureExternalEvents
SOIL ATLAS OF ASIA
2ND EDITORIAL BOARD MEETING
RURAL DEVELOPMENT ADMINISTRATION, NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES,
JEONJU, REPUBLIC OF KOREA | 29 APRIL – 3 MAY 2019
Markus Anda (Indonesia)
Item 8: WRB, World Reference Base for Soil ResoucesExternalEvents
SOIL ATLAS OF ASIA
2ND EDITORIAL BOARD MEETING
RURAL DEVELOPMENT ADMINISTRATION, NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES,
JEONJU, REPUBLIC OF KOREA | 29 APRIL – 3 MAY 2019
Satira Udomsri (Thailand)
SOIL ATLAS OF ASIA
2ND EDITORIAL BOARD MEETING
RURAL DEVELOPMENT ADMINISTRATION, NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES,
JEONJU, REPUBLIC OF KOREA | 29 APRIL – 3 MAY 2019
Shree Prasad Vista (Nepal)
Item 6: International Center for Biosaline AgricultureExternalEvents
SOIL ATLAS OF ASIA
2ND EDITORIAL BOARD MEETING
RURAL DEVELOPMENT ADMINISTRATION, NATIONAL INSTITUTE OF AGRICULTURAL SCIENCES,
JEONJU, REPUBLIC OF KOREA | 29 APRIL – 3 MAY 2019
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
Operation “Blue Star” is the only event in the history of Independent India where the state went into war with its own people. Even after about 40 years it is not clear if it was culmination of states anger over people of the region, a political game of power or start of dictatorial chapter in the democratic setup.
The people of Punjab felt alienated from main stream due to denial of their just demands during a long democratic struggle since independence. As it happen all over the word, it led to militant struggle with great loss of lives of military, police and civilian personnel. Killing of Indira Gandhi and massacre of innocent Sikhs in Delhi and other India cities was also associated with this movement.
Embracing GenAI - A Strategic ImperativePeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
Macroeconomics- Movie Location
This will be used as part of your Personal Professional Portfolio once graded.
Objective:
Prepare a presentation or a paper using research, basic comparative analysis, data organization and application of economic information. You will make an informed assessment of an economic climate outside of the United States to accomplish an entertainment industry objective.
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdfTechSoup
In this webinar you will learn how your organization can access TechSoup's wide variety of product discount and donation programs. From hardware to software, we'll give you a tour of the tools available to help your nonprofit with productivity, collaboration, financial management, donor tracking, security, and more.
Francesca Gottschalk - How can education support child empowerment.pptxEduSkills OECD
Francesca Gottschalk from the OECD’s Centre for Educational Research and Innovation presents at the Ask an Expert Webinar: How can education support child empowerment?
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
1. Livestock vaccines: development and
market access
FAO symposium: The Role of Agricultural Biotechnologies in Sustainable Food Systems and Nutrition
Session: Facing the challenges of climate change: Adaptation in the livestock and fishery sectors
Speaker: Jean de Foucauld, Senior Biology Expert, Ceva Santé Animale
speaking on behalf of HealthforAnimals
Rome, February 2016
2. 2
80+% global animal health sector
In addition, 29 regional/national associations
represent 100+ smaller/medium-sized
companies.
About HealthforAnimals
• global representative body companies/associations
• R&D, manufacturing and commercialisation
• veterinary medicines, vaccines + other animal health products
Animal health companies provide value to society:
• by protecting animals and humans from diseases
• keeping pets and food-producing animals healthy
• public health benefits we bring include:
• safer and more secure food supplies
• more efficient production for increased food supply
• improved reactivity and sustainability
• prevention of the transmission of zoonotic diseases
HealthforAnimals Top 10 global companies
3. 3
www.healthforanimals.org
• Climate change along with other factors like increased movement of people
and animals, triggers new and fast moving livestock disease patterns
• Almost every day we learn of news related to this (the Philippines very recently
with Newcastle disease in poultry)
• Vaccines who are essential of almost all livestock breeding systems are
already available to fight some of these diseases but new vaccines are also
needed
• Gene technology introduced some 30 years ago has allowed developing
vaccines that are already saving millions of livestock and new innovative
solutions are ready in the laboratory
• Delivering new solutions to all customers starts with the science but much
more is needed and this makes the whole difference!
Introduction and setting the scene
4. 4
• Of 25 major human diseases, 17 are zoonoses (underligned)
• Of 1500 human infectious diseases, about 65% zoonotic
• One new disease emerges every 7 months
Climate change – zoonotic diseases
Malaria
Cholera
Influenza
Diarrhoea
Filiariasis
Int. Nematodes
Sleeping sickness
Chagas
West Nile
Yellow Fever
Lyme disease
Meningococcal
meningitis
Leishmaniasis
Dengue
Japanese encephalitis
St Louis encephalitis
Rift Valley Fever
Ross River Fever
Murray Valley Fever
Schistosomiasis
STDs
Trachoma
Tuberculosis
River blindness
Childhood disease
High climate sensitivity
Source: International Livestock Reseach Institute: Climate Change and Zoonoses Adaptation and Mitigation
5. 5
www.healthforanimals.org
• African swine fever (ASF): African disease threatens global $150 billion/year pig
industry
• Contagious bovine pleuropneumonia (CBPP): regional losses to CBPP amount to ~
$60 million/year
• East Coast fever (ECF) : regional losses exceed $300 million/year; kills ~ 1million
cattle/year
• Rift Valley Fever (RVF): small ruminants, cattle and human. 2006/7 outbreak Kenya
cost ~ $30 million, 309 human cases in Kenya, Somalia and Tanzania; 140 deaths
• Trypanosomosis: ruminants and for some species humans; affecting YYY
Vaccines availability for these diseases:
• ASF – no vaccine
• CBPP – duration of immunity is short lived and vaccine can cause side reactions
• ECF – live vaccine difficult to manufacture, needs liquid nitrogen cold chain and
oxytetracycline co-treatment - costs 8~12 $/dose
• RVF – vaccine can cause abortions in sheep; human vaccine not available
• Trypanosomosis: no vaccine
Source: International Livestock Reseach Institute: Climate Change and Zoonoses Adaptation and Mitigation
Research is still needed
6. 6
www.healthforanimals.org
• There are three pillars to bring vaccine innovation to livestock in a timely
manner
• A good scientific demonstration of a vaccine solution
• A proper vaccine development (up to the capacity to produce and get the
marketing authorisations in the target countries)
• The right access to the market
• In addition we may need: DIVA system, protection of newborns, gestating
animals, wildlife, single vaccination, reduction of transmission, eradication,
establishment of vaccine banks for rapid deployment?
• Looking at science, there are a few examples of new technologies that have
already, or will help, fighting livestock diseases (if put on the market)
• Let us discuss some of them: avian influenza H5 vaccine, HVT and Pox
platforms and non-replicative ‘replicon’ technology (used for RVF candidate
vaccine).
What is needed to access customers ?
7. 7
www.healthforanimals.org
• It is a major disease of poultry: H9, H7 and H5
• Can become highly virulent (H5&7)
• Can become a zoonosis with two situations
• The humans being infected by poultry but not able to transmit the disease
• The virus becomes contagious between humans, not needing anymore
the poultry host
• The main difficulties to fight the disease are:
• Reducing the contagion, by reducing circulation of the virus
• Meaning reducing excretion from infected birds (not only the symptoms)
• Mass vaccination as early as possible (in presence of maternal
antibodies)
Avian Influenza example
8. 8
www.healthforanimals.org
Goal of AI vaccines
1 – Infection
3 – Re-excretion
2 - Clinical expression
HIGHER RESISTANCE
TO INFECTION
REDUCTION OF RE-EXCRETION
CLINICAL PROTECTION
+
+
9. 9
www.healthforanimals.org
• No conventional vaccine could do this
• This is possible with a vector vaccine (Vectormune® AI)
• A vector platform: HVT
• A avian influenza targeted gene: H5 (Europe 2006)
• Vaccine tested in different conditions:
• Different challenge strains from very different parts of the world (see later)
• Different bird categories including for very long duration of immunity
• With maternal antibodies
• Registered in the USA (vaccine bank)
• Registered in different countries where authorities have decided to vaccinate
• First results very encouraging ; for this market access is key and in this case,
access to the hatcheries
Avian Influenza example
10. 10
H5N1
AIV
HA
HA gene
AIV genome
HVT
Non essential
gene
HVT = Vector
HVT
Insertion site
AIV = Donor
FC 126 strain
A/swan/Hungary/4999/2006
(H5N1 clade 2 – subclade 2 AIV strain)
Inserted modified
HA gene
« insert »
12. 12
Protection ≥ 80%
Significant
reduction of shedding
Cross clade
efficacy
of
Vectormune® AI
Vietnam 2004
Mongolia 2005
Egypt 2008
Indonesia 2007
Bangladesh 2011
Hungary 2006
Egypt 2010
Indonesia 2010
Egypt 2008
Egypt 2011
Germany 2014
13. 13
www.healthforanimals.org
• What is next for HVT-AI?
• Improve market access for AI vaccination in hatcheries: registration,
government policies, marketing…
• Update the inserted gene
• HVT as platform for poultry disease vaccines
• Well known, very safe for the target species and environment
• Works in presence of maternal antibodies and provides long duration of
immunity
• Used in different registered vaccines (7 different constructs registered)
• Tens of billion doses used in many different countries of the world
• In the case of AI: updating the construct with newest AI serotype and
clade is fast and easy (using the same genetic engineering technology)
• Should avoid going through the full development & registration processes
(see later discussion on this)
• Canarypox vector platform for mammalian diseases is also a strong candidate
as an estimated platform
HVT-AI and other vector examples
14. 14
www.healthforanimals.org
• Sub-unit antigens
• Well known ‘antigen factories’ like Baculovirus, yeast, Pichia pastoris…
• Find the gene of interest
• The relevant adjuvant
• Fast to build and develop
• ‘Simple’ on a regulatory standpoint (inactivated ‘by nature’)
• Questions: maternal antibodies, duration of immunity, broadness of
protection…
• Can be very useful with some diseases: best example: PCV2; was tested
with Flu
Other interesting technologies
15. 15
www.healthforanimals.org
• Replicon vaccine
• Not inactivated, non-replicating virus
• Vaccine build with targeted gene of interest
• Able to enter target cells of vaccinated animals
• Gene of interest can be expressed by the cells: immune response
• But does not have the genetic material to multiply; no spreading to other
cells!
• Fast to build constructs
• Safe and a good candidate for registration as a technology/platform
(USDA already allowed this)
• Questions: duration of immunity, efficacy (but this is true for all construct
as it is a question of the good choice of targeted genes)
Other interesting technologies
17. 17
Rift valley fever example
• Arbovirus, Bunyaviridae family;
mosquito vector and direct contamination
•Highly related to climate changes
• Ruminants (domestic, wild): economic losses due to death
and abortion
• Febrile disease in humans, fatal due to complications in <1% of cases
•Vaccines are not satisfactory
Culex spp Aedes sp
18. 18
A synthetic RVFV with a split M genome segment results in a
virus that is completely avirulent and highly effective vaccine
Rift valley fever example
19. 19
www.healthforanimals.org
• Development consists of establishing and validating the manufacturing
process and then testing the vaccine for its shelf life, safety and efficacy
• These steps are followed by the registration and industrialisation processes
• Manufacturing process
• It should fulfil four main goals common to all veterinary vaccines: quality,
reproducibility, stability and an adequate cost of production
• Quality has two aspects:
• producing according to acceptable standards like GMP, USDA…;
• manufacturing according to a process allowing expressing the main
safety, efficacy, stability features singled our during the
research/feasibility phase
• This involves validated control tests that are the quality markers of the
production runs; with ‘New technology’ vaccines, composed of well
defined antigens and it is easier to monitor if the explored processes are
adequate or not to fulfil the set quality, safety and efficacy goals
• Finally pilot batches are produced
Vaccine development paradigm
20. 20
www.healthforanimals.org
• Regulatory testing: vaccine pilot batches are tested according to a ‘regulatory’
analytical and clinical program covering:
• Validation of the planned manufacturing process
• Shelf life study
• Clinical trials to confirm the safety and efficacy claims
• Specific tests are required for genetically engineered non-inactivated
vaccines
• Timing and budget: for a new innovation (never registered before) from proof
of concept to the establishment of the ‘data package’ allowing the different
registration procedures:
• Poultry: 2 to 3 years and 2 to 4 M€
• Ruminants: 3 to 5 years and 4 to 10 M€
(depending on disease and claims)
• This could be reduced if the technology is already assessed on a
regulatory standpoint (see after)
Vaccine development paradigm
21. 21
www.healthforanimals.org
• Registration dossier and procedures: all relevant data are gathered to
prepare dossiers for:
• Getting GMP permit in the country of origin (granted for each specific
vaccine)
• In the case of live genetically engineered vaccines a specific field
release procedure is usually needed
• If required by the target countries, to apply for a marketing authorisation
in the country of origin, even if this is not relevant for them (no disease
or market)
• Assessment by target country authorities of dossiers for new
technology vaccines:
• Specific training on these new technologies?
• Assessment by authorities of country of origin needed or not?
• How to deal with this procedure when urgent?
Vaccine registration paradigm
22. 22
www.healthforanimals.org
• Registration dossier and procedures: timing
• Marketing authorisation timing (usual procedures):
-2,5 to 3 years, including specific procedure for field release, if the country
of origin is in Europe or the USA;
-then an additional 2 years to get the marketing authorisation in the target
countries. Can be much longer for ‘new technology’ vaccines.
• In any case, a long process…
Vaccine registration paradigm
23. 23
www.healthforanimals.org
• What can be improved here to securely speed up the processes?
• Research phase is not the issue (with exceptions) as it now quick to
propose solutions
• Ideally the proposed solutions should be around already known
platforms: sub-unit antigens, live HVT vector, non-replicative replicon
systems… with predictable (not depending on a specific construct) and
clear safety benefits for the target species and the environment
• Assessment: when the proposed technology was already assessed by
registration authorities and Bio-Safety committees (from previously
registered vaccines): less tests might be asked for; focus can be on
efficacy with some confirmation safety and quality tests
• The US authorities (USDA) has already implemented this with some
platforms and technologies
Vaccine development & registration
24. 24
www.healthforanimals.org
• What can be improved here to speed up the processes?
• When there is no disease in the country of origin, should authorities of
the target countries ask the applicant to register the vaccine at home?
• If not, how can they be sure that the proposed vaccine is safe?
• Use scientific assessment from recognised expert groups
• This is essential for target country authorities that had no chance to
be trained for ‘new technology’ vaccines
• Role of OIE, FAO, VICH to establish such recommend assessment
team, could be very important in this matter
• Once receiving a positive assessment, Authorities of the target
countries might give an exceptional license waiting for more data for the
final marketing authorisation (identical to systems in Europe and
elsewhere)
• Favouring establishment of regional vaccine players in the affected
zones? This is an important long-term goal; but wherever you are, you
need the same very experienced teams; also regulatory barriers are not
necessarily down between countries within a same region
(harmonisation is on the way though)
Vaccine development & registration
25. 25
www.healthforanimals.org
Market access covers many aspects:
• Production: is there enough capacity to cover all the needs?
• Tight markets: with the increased recognition of vaccines as key and
comparatively cheap tools for healthy livestock and with the phasing out of
some alternative treatment solutions, we see already periods with tight
supply of vaccines in many parts of the world
• Manufacturing requires very skills teams that can only be built over many
years
• Extending capacity depends on two conditions:
• private initiative, willing to bet on new markets (including the ones
created by emerging diseases)
• Good policies helping these initiatives succeed
What about market access?
26. 26
www.healthforanimals.org
• Registration procedures:
• A fair and predictable process ensuring that safe, efficacious vaccines
are registered
• Many challenges to implement this when there are urgent needs; some
solutions were already suggested
• Other market access challenges (basic but so important!):
• Supply chain: from the manufacturing site to the end customers
• In a few parts of the world (where these vaccines are in great needs)
this is challenging
• Transport and cold chain: refrigerated trucks and fridges
• More regional/local distributors close to the customers
• Veterinarians and vaccination/health technicians:
• More are needed on the field
• More trainings
• More schools
• Unfair competition
• With counterfeit products
• With ‘easier-access’ markets
What about market access?
27. 27
www.healthforanimals.org
• Climate change along with other factors, triggers new and fast moving
disease patterns against which vaccines can make the difference
• New vaccine technologies using genetic engineering are now really mature
and already saving billions of animals every year; new ideas are ready to be
implemented; more effort is needed for some key unmet needs
• Development, registration, production of vaccines can be managed only by
very skilled teams/companies which are not so many in the world
• Vaccine registration procedure and timing might be challenging in many
occasions especially when new technologies are involved and needs are
urgent
• Accessing customers in some markets is sometimes very difficult and unfair
market competition can happen when vaccine supply is tight
• A better network of veterinarian, technicians and distributors, close to the
final customers are needed in many countries
Conclusions on the situation
28. 28
www.healthforanimals.org
• All stakeholders must work on proactive and ambitious plans to ensure that
new vaccine solutions go from the laboratory to all customers, helping
companies/organisations which are willing to address these new markets
• Funding research
• Establishing solid technology platforms on which development and
regulatory experience can be built for future vaccines
• Set one reference assessment team for regions that do not have yet the
experience/expertise of ‘new technology’ vaccines
• Promote training and development of local and regional veterinary and
technical networks
• Establish new veterinary and health technician schools
In conclusion, in this context of climate change, science and
technology can do a lot, but much more is needed to get the vaccines
to the customers, where policy makers can make the whole difference!
Conclusions and proposed solutions
29. 29
www.healthforanimals.org
My thanks to:
• Carel du Marchie Sarvaas, Executive Director, HealthforAnimals
• Jeroen Kortekaas, PhD, Central Veterinary Institute, Wageningen University
and Research Centre, the Netherlands
• Yannick Gardin, Director Science and Innovation, Ceva Animal Health
jean.de-foucauld@ceva.com
Thanks
30. 30
www.healthforanimals.org
HealthforAnimals
168 Avenue de Tervueren
1150 Brussels, Belgium
info@healthforanimals.org
www.healthforanimals.org
twitter! @health4animals
Ceva Santé Animale
10 Avenue de la Ballastière
33500 Libourne – France
Jean de Foucauld
jean.de-foucauld@ceva.com
www.ceva.com
Thank you